88 related articles for article (PubMed ID: 1457190)
21. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
22. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
Moore A; McCarthy L; Mills KH
Vaccine; 1999 Jun; 17(20-21):2517-27. PubMed ID: 10418898
[TBL] [Abstract][Full Text] [Related]
23. Expression and identification of immunological activities of the HIV-gp120N-human interferon gamma fusion protein.
Feng TT; Zhao G; Yao HP; Wang QP; Wu NP
Anat Rec (Hoboken); 2009 Mar; 292(3):381-6. PubMed ID: 19248157
[TBL] [Abstract][Full Text] [Related]
24. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.
Bortolatto J; Borducchi E; Rodriguez D; Keller AC; Faquim-Mauro E; Bortoluci KR; Mucida D; Gomes E; Christ A; Schnyder-Candrian S; Schnyder B; Ryffel B; Russo M
Clin Exp Allergy; 2008 Oct; 38(10):1668-79. PubMed ID: 18631348
[TBL] [Abstract][Full Text] [Related]
25. Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro.
Krivorutchenko YL; Andronovskaja IB; Hinkula J; Krivoshein YS; Ljungdahl-Ståhle E; Pertel SS; Grishkovets VI; Zemlyakov AE; Wahren B
Vaccine; 1997; 15(12-13):1479-86. PubMed ID: 9302764
[TBL] [Abstract][Full Text] [Related]
26. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Evans TG; McElrath MJ; Matthews T; Montefiori D; Weinhold K; Wolff M; Keefer MC; Kallas EG; Corey L; Gorse GJ; Belshe R; Graham BS; Spearman PW; Schwartz D; Mulligan MJ; Goepfert P; Fast P; Berman P; Powell M; Francis D;
Vaccine; 2001 Feb; 19(15-16):2080-91. PubMed ID: 11228380
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
28. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
[TBL] [Abstract][Full Text] [Related]
29. Diesel exhaust, carbon black, and silica particles display distinct Th1/Th2 modulating activity.
van Zijverden M; van der Pijl A; Bol M; van Pinxteren FA; de Haar C; Penninks AH; van Loveren H; Pieters R
Toxicol Appl Pharmacol; 2000 Oct; 168(2):131-9. PubMed ID: 11032768
[TBL] [Abstract][Full Text] [Related]
30. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
31. Influence of aluminum-based adjuvant on the immune response to multiantigenic formulation.
Iglesias E; Franch O; Carrazana Y; Lobaina Y; García D; Sanchez J; García J; Urquiza D; Muzio V; Guillén G; Aguilar JC
Viral Immunol; 2006; 19(4):712-21. PubMed ID: 17201666
[TBL] [Abstract][Full Text] [Related]
32. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
34. Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants.
Lofthouse SA; Andrews AE; Nash AD; Bowles VM
Vaccine; 1995 Aug; 13(12):1131-7. PubMed ID: 7491821
[TBL] [Abstract][Full Text] [Related]
35. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.
Powell MF; Eastman DJ; Lim A; Lucas C; Peterson M; Vennari J; Weissburg RP; Wrin T; Kensil CR; Newman MJ
AIDS Res Hum Retroviruses; 1995 Feb; 11(2):203-9. PubMed ID: 7742035
[TBL] [Abstract][Full Text] [Related]
36. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A.
Moschos SA; Bramwell VW; Somavarapu S; Alpar HO
Vaccine; 2006 Feb; 24(8):1081-6. PubMed ID: 16219395
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.
van de Wijgert JH; Verheul AF; Snippe H; Check IJ; Hunter RL
Infect Immun; 1991 Aug; 59(8):2750-7. PubMed ID: 1855991
[TBL] [Abstract][Full Text] [Related]
38. Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
Shimizu T; Iwamoto Y; Yanagihara Y; Ikeda K; Achiwa K
Int J Immunopharmacol; 1992 Nov; 14(8):1415-20. PubMed ID: 1464473
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant requirements for protective immunization of mice using a Trypanosoma cruzi 90K cell surface glycoprotein.
Scott MT; Bahr G; Moddaber F; Afchain D; Chedid L
Int Arch Allergy Appl Immunol; 1984; 74(4):373-7. PubMed ID: 6429057
[TBL] [Abstract][Full Text] [Related]
40. Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice.
Katayama S; Oda K; Ohgitani T; Hirahara T; Shimizu Y
Vaccine; 1999 Jun; 17(20-21):2733-9. PubMed ID: 10418925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
